Launch Mitsubishi Pharma Europe’s anticoagulant Exembol® (argatroban) after it received acceptance for use as a treatment for patients with heparin-induced thrombocytopenia type II (HIT).
HIT (type II) is a rare condition with potentially life threatening outcomes for patients. ROAD launched a media campaign targeting haematology, phlebotomy, ICU and cardiovascular trade titles and journals, to raise awareness of Exembol® as a new drug for the treatment of HIT.
Articles were secured in Journal of Anaesthesia and the Journal of Intensive Care, and coverage was secured in 30+ targeted medical and pharmaceutical titles, generating 2,089,147 opportunities to be seen.
